title: Research on the epigenetic modification of pancreatic cancer vaccine.
abstract: Pancreatic cancer is characterized as a type of gastrointestinal tumor with a poor prognosis and high degree of malignancy. CIITA gene was found highly methylated in pancreatic carcinoma cell line PANC-1 and responsible for the low expression of MHC-II that may lead to immune evasion. Here, we tried to prepare pancreatic cancer vaccine with PANC-1 cells via epigenetic modification to enhance the MHC-II expression. Then the vaccine was injected into C57BL/6J mice and the effect was examined. Our study found that the vaccine could promote the proliferation of antigen-specific T cells, enhance the killing activity of cytotoxic lymphocytes (CTL), promote Th1-type cells mediated secretion of cytokines IFN-gamma and IL-2 while inhibiting Th2-type cells mediated secretion of IL-4, and inhibit the secretion of TGF-beta. Generally, the epigenetically modified vaccine could enhance the body's anti-tumor immune response, providing feasibility research on cancer vaccine for therapy of pancreatic cancer.
authors.forename: Wei
authors.initials: W
authors.lastname: Cao
authors.forename: Guoxiong
authors.initials: G
authors.lastname: Zhou
authors.forename: Ji
authors.initials: J
authors.lastname: Qiu
authors.forename: Liangfeng
authors.initials: L
authors.lastname: Xu
authors.forename: Xiaoling
authors.initials: X
authors.lastname: Ding
authors.forename: Haifeng
authors.initials: H
authors.lastname: Zhang
authors.forename: Xiaorong
authors.initials: X
authors.lastname: Zhou
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology; D016923:Cell Death / Q000187:drug effects / Q000235:genetics; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D016207:Cytokines / Q000032:analysis / Q000378:metabolism; D004248:DNA (Cytosine-5-)-Methyltransferases / Q000037:antagonists & inhibitors; D019175:DNA Methylation / Q000187:drug effects / Q000235:genetics*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D044127:Epigenesis, Genetic / Q000187:drug effects / Q000235:genetics*; D005802:Genes, MHC Class II / Q000187:drug effects / Q000235:genetics; D056572:Histone Deacetylase Inhibitors / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D009687:Nuclear Proteins / Q000187:drug effects / Q000235:genetics; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000276:immunology*; D013154:Spleen / Q000166:cytology; D018417:Th1 Cells / Q000378:metabolism; D018418:Th2 Cells / Q000378:metabolism; D015534:Trans-Activators / Q000187:drug effects / Q000235:genetics
chemical_list: D019496:Cancer Vaccines; D016207:Cytokines; D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D015534:Trans-Activators; D004248:DNA (Cytosine-5-)-Methyltransferases